World Congress on Precision Medicine and Genomic Healthcare

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Next-generation sequencing (NGS)

Massively parallel sequencing that reads millions of DNA fragments at once; the workhorse technology behind panel, exome and genome testing discussed across the conference tracks.

2

Whole genome sequencing (WGS)

Sequencing of the complete coding and non-coding genome, used for rare disease diagnosis, oncology profiling and population-scale research.

3

Whole exome sequencing (WES)

Sequencing restricted to protein-coding regions, a common cost-controlled route for rare disease and clinical research programmes.

4

Variant calling

The computational step that identifies differences between a sequenced sample and a reference genome, including SNVs, indels and structural variants.

5

ACMG classification

The five-tier framework (pathogenic, likely pathogenic, uncertain significance, likely benign, benign) used to grade germline variants in clinical reporting.

6

Variant of uncertain significance (VUS)

A variant with insufficient evidence to be classed as pathogenic or benign; a recurring operational burden for clinical genetics teams.

7

Liquid biopsy

Testing of blood or other body fluids for circulating tumour DNA and other biomarkers, an alternative or complement to tissue biopsy in oncology.

8

ctDNA

Circulating tumour DNA shed into plasma by tumour cells; used for minimal residual disease monitoring, resistance profiling and therapy selection.

9

Spatial transcriptomics

Gene expression profiling that preserves tissue location, linking molecular data to histology in tumour and developmental research.

10

Single-cell sequencing

Sequencing of individual cells to resolve cell-type heterogeneity in tumours, immune populations and tissue atlases.

11

Multi-omics

Integration of genomics with transcriptomic, proteomic, epigenomic or metabolomic data to build a fuller model of disease biology.

12

Pharmacogenomics

Use of genetic variation to predict drug response or toxicity, informing dosing and treatment selection.

13

Companion diagnostic

A test required alongside a specific therapy to identify patients likely to benefit; a key commercial intersection of diagnostics and pharma at this show.

14

Cell-free DNA (cfDNA) screening

Prenatal screening that analyses fetal DNA fragments in maternal blood, widely used for aneuploidy risk assessment.

15

Analytical and clinical validation

The evidence package showing a genomic test measures what it claims (analytical) and predicts the clinical state it claims (clinical) before routine use.

16

Secondary and tertiary analysis

Secondary analysis covers alignment and variant calling; tertiary analysis covers annotation, filtering, interpretation and reporting.

17

Reference standard

A characterised sample or dataset used to benchmark assay performance, calibrate pipelines and support accreditation.

18

Biobank

A governed collection of biological samples and linked data used for research, validation and cohort studies, subject to consent and ethics rules.